Journal of Clinical Trials
Open Access

Department of Medical Managed Markets and Health Economics and Outcomes Research, Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, South San Francisco, CA, USA

Publications

• Research Article   
  Prognostic Value of Risk Assessment Tools for Patients with Pulmonary Arterial Hypertension in WHO Functional Class II: A Post Hoc Analysis of the EARLY Trial
  Author(s): Nick H. Kim*, Cassandra A. Lickert, Janis A. Pruett, Carol Zhao and William Drake III
  
  Background: Current practice guidelines for patients with Pulmonary Arterial Hypertension (PAH) recommend a multidimensional risk assessment, but World Health Organization (WHO) Functional Class (FC) remains a main criterion for treatment decisions. Objectives: A post hoc analysis was conducted to determine if different risk assessment tools evaluated in PAH registry populations can identify patients in WHO FC II at higher risk of death. Methods: Patients in the randomized, controlled EARLY trial (NCT00091715; N=185), which exclusively enrolled patients in FC II, were stratified into three categories—low-, intermediate-, and high-risk—using the original REVEAL risk calculator, revised REVEAL risk calculator 2.0, COMPERA categorical score, and two FPHN methods (invasive and non-invasive) counting low-ris.. Read More»
  

  Abstract HTML PDF